Management of Elevated Hemoglobin

Introduction to Treatment

• The American Society of Clinical Oncology and the National Kidney Foundation recommend maintaining hemoglobin at the lowest concentration needed to avoid transfusions, with upper limits of 12 g/dL in cancer patients and 13 g/dL in chronic kidney disease patients, based on moderate to high-quality evidence 1, 2
• The American Society of Clinical Oncology recommends decreasing the dose of erythropoiesis-stimulating agents (ESAs) by 25-40% when hemoglobin reaches a level needed to avoid transfusion or increases >1 g/dL in 2 weeks, and withholding ESA if hemoglobin exceeds target level, with a strength of evidence based on clinical guidelines 1

Dose Modification and Target Hemoglobin

• For patients receiving ESAs, the dose should be decreased by 25-40% when hemoglobin reaches a level needed to avoid transfusion or increases >1 g/dL in 2 weeks, and restarted at 25-40% below previous dose when hemoglobin approaches a level where transfusion may be required, with a strength of evidence based on clinical guidelines 1
• The target hemoglobin level should be maintained at the lowest concentration needed to avoid transfusions, with an upper limit of 12 g/dL in cancer patients and 13 g/dL in chronic kidney disease patients, based on moderate to high-quality evidence 1, 2

Discontinuation of ESAs

• The American Society of Clinical Oncology recommends discontinuing ESAs if no response after 8 weeks of therapy, measured by hemoglobin levels or continuing need for transfusions, with a strength of evidence based on clinical guidelines 1
• The European Society for Medical Oncology and the American Society of Clinical Oncology recommend discontinuing erythropoiesis-stimulating agents if hemoglobin exceeds 12 g/dL 3, 1
• The American Journal of Kidney Diseases recommends that hemoglobin targets should not exceed 13.0 g/dL when using erythropoiesis-stimulating agents in patients with chronic kidney disease 2

Monitoring and Treatment of Complications

• Patients with elevated hemoglobin are at high risk for thrombotic events, including deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction, and require close monitoring 4
• Regular monitoring of complete blood count and assessment for symptoms of hyperviscosity, such as headache, visual disturbances, dizziness, and paresthesias, are essential in patients with elevated hemoglobin 4, 5
• The American College of Physicians suggests a transfusion threshold of Hgb <7 g/dL in stable patients with normal or low hemoglobin, while higher thresholds (Hgb <8-10 g/dL) may be appropriate in patients with cardiac disease 4

Treatment of Specific Conditions

• The following treatment guidelines are recommended:

• The National Comprehensive Cancer Network recommends phlebotomy to maintain hematocrit <45% and consideration of cytoreductive therapy, such as hydroxyurea, in patients with polycythemia vera 3, 1
• For trauma patients with elevated Hb requiring neurosurgery, maintenance of Hb >7 g/dL and ensuring platelet count >50,000/mm³ and PT/aPTT <1.5 normal control is recommended 6